RENNOVA HEALTH, INC. (NASDAQ:RNVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Dr. Kamran Ajami (Chairman)
John Beach
Gary L. Blum
In addition to each being “independent,” the Board of Directors determined that each of Mr. Blum and Mr. Beach is “financially literate” as required by the Listing Rules of The Nasdaq Stock Market and that Mr. Beach qualifies as an “audit committee expert” as defined by the rules and regulations of the Securities and Exchange Commission and meets the qualifications of “financial sophistication” under the Listing Rules of The Nasdaq Stock Market. As a result of the above appointments, each Committee is now made up of Mr. Blum, Mr. Beach and Dr. Ajami, three independent directors.
About RENNOVA HEALTH, INC. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
